Clinical trial NCT01383109: Human Mass Balance Study of Pyronaridine
Official title: A Human Mass Balance Study of Pyronaridine Using Accelerator Mass Spectrometry
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Malaria
Keywords: Mass Balance
Accelerated Mass Spectrometry (AMS)
microdose
Focus of the study: ADME
Lead sponsor: Medicines for Malaria Venture
Sponsor class: OTHER
Collaborators: name: Shin Poong Pharmaceuticals
First posted: 2011-06-28
Enrollment: 6
Sex: MALE
Minimum age (years): 40
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The combination of pyronaridine and artesunate is an antimalarial therapy in development. This mass balance study is intended to determine the rate and extent of excretion of total radioactivity in urine and feces following administration of a single oral micro-dose of 14C-pyronaridine in humans.

Detailed description: This is a monocenter, open-label, non-placebo-controlled, single-group, single-dose study. Six male subjects will receive a single dose of Pyronaridine 720 mg orally administered together with 14C-Pyronaridine (approx. 100 µg, 800 nCi (29600 Bq)).

Safety measurements (12-lead ECG, vital signs, blood chemistry and haematology) and adverse events will be monitored throughout the study. Subjects will come to the clinic the evening before the dosing of Pyronaridine. After the drug intake at day 1, subjects will have regular in-house periods for specimen collection up to 87 days after the drug administration. Blood, feces and urine will be collected during the hospitalisation periods. Samples will be analyzed for radioactivity by Accelerator Mass Spectrometry (AMS).

Eligibility criteria: Inclusion Criteria:

1. Male subjects between the ages of 40 and 55 years with a body weight between 60 and 90 kg and a body mass index calculated using Quetelet's Index - weight (kg)/height2 (m2) between 18.5 - 30.0
2. Signed and dated written informed consent form (ICF) before undergoing any study related activities, including discontinuation of any prohibited medications
3. Medically normal subjects with no significant abnormal findings at the screening physical examination as evaluated by the investigator
4. Strictly normal values of ALT, AST and bilirubin and normal or abnormal and clinically insignificant results (if agreed by the Investigator and the Sponsor on a case by case evaluation) of the other blood and urine laboratory parameters at screening
5. All sexually active male subjects and their partners are willing to undergo contraception as follows:

   All male subjects, including those who are sterilised (i.e., vasectomy), should use a condom. Their female partner must also use at least 1 of the medically acceptable forms of contraceptives listed below. Male subjects must not donate sperm or have unprotected sex during the study and until 87 days after taking the dose of investigational product.

   Medically acceptable contraceptives for this study are:

   Condoms in addition to:
   * Intrauterine devices
   * Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring)
   * Diaphragms with spermicidal cream or gel
   * Cervical cap with spermicidal cream or gel
   * Spermicidal foam
6. The ability to understand the requirements of the study and willingness to comply with all study procedures

Exclusion Criteria:

1. Known history or evidence of clinically significant disorders such as cardiovascular (including arrhythmia, acute QTc interval greater or equal to 450 mseconds), respiratory (including active tuberculosis), hepatic, renal, gastrointestinal, immunological (including active HIV-AIDS), neurological (including auditory), endocrine, infectious, malignancy, psychiatric or other clinical abnormality
2. Known history of hypersensitivity, allergic or adverse reactions to Pyronaridine
3. Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody (HCV Ab)
4. Seropositive HIV antibody
5. Previous participation in any clinical study with Pyramax
6. Presence or recent history (last two years) of tobacco abuse (≥10 cigarettes/day)
7. Known or suspected alcohol abuse or illicit drug use in the last 10 years before the study start or positive findings on urine drug screen
8. Intake of grapefruit and grapefruit juice alcoholic beverages or caffeine-containing food or beverages, such as coffee, tea, chocolate, or cola, 48 hours before study drug administration
9. Use of over-the-counter (OTC) medications, including vitamins, analgesics, or antacids, 1 week before the study start
10. Use of prescription medications 14 days before the study start or required chronic use of any prescription medication
11. Use of enzyme-altering agents (e.g., barbiturates, phenothiazines, cimetidine, etc.) within 30 days or 5 half lives, whichever the longer, before the study start
12. Plasma donation 1 month before the study start
13. Blood donation of 450 mL or more in the last 3 months before the study start
14. Participation in other clinical trials during the previous month in which an investigational drug or a commercially available drug was tested
15. Exposure to artificial ionizing radiation in the last 12 months (e.g., x-ray investigation, isotope studies)

Primary outcomes:
measure: Analysis of 14C-Pyronaridine Total Radioactivity in Urine
timeFrame: 2064 hours
measure: Analysis of 14C-Pyronaridine Total Radioactivity in Feces
timeFrame: 2064 hours
Secondary outcomes:
measure: Total Radioactivity in Blood: AUC0-t, AUC0-∞
timeFrame: 42 days
measure: Total Radioactivity in Blood: Cmax
timeFrame: 42 days
measure: Total Radioactivity in Blood: Half-life, Tmax
timeFrame: 42 days
Other outcomes:
Locations:
city: Allschwil
country: Switzerland
facility: Covance Clinical Research Unit AG
state: Basel
Study officials:
affiliation: Medicines for Malaria Venture
name: Isabelle Borghini Fuhrer, PhD
role: STUDY_DIRECTOR
References: